Mark L. Tykocinski
President bij Thomas Jefferson University
Profiel
Mark L.
Tykocinski was the founder of KAHR Medical Ltd.
founded in 2005, where he held the title of Research Officer.
Currently, he is the President of Thomas Jefferson University.
Previously, he held the position of Senior Vice President at Thomas Jefferson University, Principal at the University of Pennsylvania, Dean at Sidney Kimmel Medical College, and President at the American Society for Investigative Pathology.
Actieve functies van Mark L. Tykocinski
| Bedrijven | Functie | Begin |
|---|---|---|
| Thomas Jefferson University | President | - |
Eerdere bekende functies van Mark L. Tykocinski
| Bedrijven | Functie | Einde |
|---|---|---|
American Society for Investigative Pathology
 American Society for Investigative Pathology BiotechnologyHealth Technology The American Society for Investigative Pathology operates as a biotechnology company. | President | - |
| University of Pennsylvania | Corporate Officer/Principal | - |
| Sidney Kimmel Medical College | Corporate Officer/Principal | - |
| Thomas Jefferson University | Corporate Officer/Principal | - |
KAHR Medical Ltd.
 KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Founder | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |
American Society for Investigative Pathology
American Society for Investigative Pathology BiotechnologyHealth Technology The American Society for Investigative Pathology operates as a biotechnology company. | Health Technology |
